Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease
- 62 Downloads
Falls in patients with Parkinson’s disease (PD) are associated with cognitive, specifically attentional impairments and with losses in cholinergic projection systems. We previously established an animal model of the combined basal forebrain cholinergic—striatal dopaminergic losses of PD fallers (Dual Lesioned, DL, rats) and demonstrated that treating DL rats with an acetylcholinesterase inhibitor (AChEI), donepezil, together with a 5HT6 receptor antagonist, idalopirdine, reduced fall frequency and improved associated aspects of the performance of DL rats traversing rotating rods.
Here, we employed a longer and more taxing rotating beam apparatus to determine the potential therapeutic efficacy of idalopirdine when combined with the pseudo-irreversible, and thus relatively long-acting, AChE- and butyrylcholinesterase- (BuChE) inhibitor rivastigmine.
As before, vehicle-treated DL rats fell more frequently, committed more slips, and exhibited more movement stoppages than intact control rats. Repeated intermittent administration of rivastigmine and idalopirdine significantly improved the performance of DL rats. Rivastigmine alone also produced strong trends for reducing falls and slips. The combination treatment was more effective than rivastigmine alone in reducing stoppages and stoppage-associated falls. As before, idalopirdine treatment alone was ineffective.
These results extend the prediction that the combined treatment with idalopirdine and an AChEI improves complex movement control and reduces the propensity for falls in patients with movement disorders. Because of the importance of finding better treatments for gait and balance deficits in PD, the present results may further motivate a clinical exploration of the usefulness of this combination treatment.
KeywordsRivastigmine Idalopirdine Acetylcholine Dopamine Basal ganglia Parkinson’s disease Falls
Compliance with ethical standards
Conflict of interest
The research described in this manuscript was supported by a grant from H. Lundbeck A/S, Valby (Denmark) to M.S. I.d.J. is an employee of H. Lundbeck.
- Amat-Foraster M, Leiser SC, Herrik KF, Richard N, Agerskov C, Bundgaard C, Bastlund JF, de Jong IEM (2017) The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture. Neuropharmacology 113:45–59CrossRefGoogle Scholar
- Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, HillsdaleGoogle Scholar
- Ferris CF, Kulkarni P, Yee JR, Nedelman M, de Jong IEM (2017) The serotonin receptor 6 antagonist idalopirdine and acetylcholinesterase inhibitor donepezil have synergistic effects on brain activity—a functional MRI study in the awake rat. Front Pharmacol 8Google Scholar
- Herrik KF, Mork A, Richard N, Bundgaard C, Bastlund JF, de Jong IE (2016) The 5-HT receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology 107:351–363CrossRefGoogle Scholar
- Kim K, Muller M, Bohnen NI, Sarter M, Lustig C (2017a) The cortical cholinergic system contributes to the top-down control of distraction: evidence from patients with Parkinson's disease. Neuroimage. https://doi.org/10.1016/j.neuroimage.2017.12.012
- Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Violi F, Mannucci PM (2013) Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 30:103–112CrossRefGoogle Scholar
- Pitchers KK, Phillips KB, Jones JL, Robinson TE, Sarter M (2017) Diverse roads to relapse: a discriminative Cue signaling cocaine availability is more effective in renewing cocaine seeking in goal trackers than sign trackers and depends on basal forebrain cholinergic activity. J Neurosci 37:7198–7208CrossRefGoogle Scholar